Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
BIIB Analyst Ratings
Moderate Buy
12 Buy
12 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BIIB Stock 12 Month Forecast
Average Price Target
$192.43
▲(27.68% Upside)
| Highest Price Target$265.00 | Average Price Target$192.43 | Lowest Price Target$135.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bernstein
Reiterated
03/05/25
Piper Sandler
Reiterated
03/04/25
Morgan Stanley
Reiterated
02/18/25
Oppenheimer
Reiterated
02/18/25
Wells Fargo
Reiterated
02/13/25
Bank of America Securities
Reiterated
02/13/25
Leerink Partners
Reiterated
02/13/25
Wedbush
Reiterated
02/13/25
Truist Financial
Reiterated
02/13/25
Scotiabank
Reiterated
02/13/25
Evercore ISI
―
Buy
―
Reiterated
02/13/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Goldman Sachs
$281→$245
Buy
62.56%
Upside
Reiterated
02/12/25
Biogen price target lowered to $245 from $281 at Goldman SachsBiogen price target lowered to $245 from $281 at Goldman Sachs
BMO Capital
$156
Hold
3.51%
Upside
Downgraded
02/12/25
Cautious Outlook on Biogen Amid Declining MS Revenues and Uncertain Growth Prospects
J.P. Morgan
$185
Hold
22.75%
Upside
Reiterated
02/12/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (NASDAQ: TXG), Biogen (NASDAQ: BIIB) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
TD Cowen
$275→$200
Buy
32.71%
Upside
Reiterated
02/12/25
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (NASDAQ: ORIC) and Biogen (NASDAQ: BIIB)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bernstein
Reiterated
03/05/25
Piper Sandler
Reiterated
03/04/25
Morgan Stanley
Reiterated
02/18/25
Oppenheimer
Reiterated
02/18/25
Wells Fargo
Reiterated
02/13/25
Bank of America Securities
Reiterated
02/13/25
Leerink Partners
Reiterated
02/13/25
Wedbush
Reiterated
02/13/25
Truist Financial
Reiterated
02/13/25
Scotiabank
Reiterated
02/13/25
Evercore ISI
―
Buy
―
Reiterated
02/13/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Goldman Sachs
$281→$245
Buy
62.56%
Upside
Reiterated
02/12/25
Biogen price target lowered to $245 from $281 at Goldman SachsBiogen price target lowered to $245 from $281 at Goldman Sachs
BMO Capital
$156
Hold
3.51%
Upside
Downgraded
02/12/25
Cautious Outlook on Biogen Amid Declining MS Revenues and Uncertain Growth Prospects
J.P. Morgan
$185
Hold
22.75%
Upside
Reiterated
02/12/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (NASDAQ: TXG), Biogen (NASDAQ: BIIB) and Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
TD Cowen
$275→$200
Buy
32.71%
Upside
Reiterated
02/12/25
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (NASDAQ: ORIC) and Biogen (NASDAQ: BIIB)
Best Analysts Covering Biogen
Which Analyst Should I Follow If I Want to Buy BIIB and Sell After:
1 Month
xxx
Success Rate
16/34 ratings generated profit
Average Return
+0.38%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.06% of your transactions generating a profit, with an average return of +0.38% per trade.
3 Months
xxx
Success Rate
20/40 ratings generated profit
Average Return
-0.95%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.95% per trade.
1 Year
Success Rate
13/40 ratings generated profit
Average Return
-6.69%
reiterated a buy rating 27 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 32.50% of your transactions generating a profit, with an average return of -6.69% per trade.
2 Years
xxx
Success Rate
11/40 ratings generated profit
Average Return
-18.62%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 27.50% of your transactions generating a profit, with an average return of -18.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BIIB Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
17
16
9
13
12
Buy
17
9
3
6
6
Hold
21
22
21
28
25
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
55
47
33
47
43
Each month's total comprises the sum of three months' worth of ratings.
BIIB Financial Forecast
BIIB Stock Forecast FAQ
What is BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is $192.43.
What is BIIB’s upside potential, based on the analysts’ average price target?
Biogen has 27.68% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BIIB a Buy, Sell or Hold?
Biogen has a consensus rating of Moderate Buy which is based on 12 buy ratings, 12 hold ratings and 0 sell ratings.
What is Biogen’s price target?
The average price target for Biogen is $192.43. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $265.00 ,the lowest forecast is $135.00. The average price target represents 27.68% Increase from the current price of $150.71.
The highest analyst price target is $265.00 ,the lowest forecast is $135.00. The average price target represents 27.68% Increase from the current price of $150.71.
What do analysts say about Biogen?
Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.
How can I buy shares of BIIB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.